ALP

:   alkaline phosphatase

ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

BUN

:   blood urea nitrogen

CRPC

:   castration‐resistant prostate cancer

CT

:   computed tomography

Hb

:   hemoglobin

LDH

:   lactate dehydrogenase

Plt

:   platelet

PSA

:   prostate‐specific antigen

TLS

:   tumor lysis syndrome

UA

:   uric acid

WBC

:   white blood cell

Keynote messageWe report a case of TLS after cabazitaxel administration for metastatic CRPC. To our knowledge, TLS after cabazitaxel therapy has not been reported previously. It is extremely important to assess the risk factors for TLS and to perform active prevention procedures in order to avoid fatal outcomes. It may be beneficial to use rasburicase in patients with established TLS.

Introduction {#iju512070-sec-0005}
============

TLS is one of the major oncological emergencies. TLS is a potentially lethal complication of anticancer treatment, and it occurs when large numbers of neoplastic cells are killed rapidly, leading to the release of large amounts of intracellular ions and metabolic byproducts into systemic circulation.[1](#iju512070-bib-0001){ref-type="ref"}, [2](#iju512070-bib-0002){ref-type="ref"}

It is typically associated with acute leukemia and high‐grade non‐Hodgkin lymphoma, and TLS in solid tumors, including prostate cancer, have been rarely reported.[3](#iju512070-bib-0003){ref-type="ref"}

Although occurrences are rare, a literature review revealed 45 case reports of TLS in patients with solid tumors, with a mortality rate of one in three in this patient set.[4](#iju512070-bib-0004){ref-type="ref"}

Clinically, TLS is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, and these metabolic abnormalities can cause renal dysfunction, arrhythmia, and seizures.[5](#iju512070-bib-0005){ref-type="ref"}

Here, we report a case of TLS after cabazitaxel administration for metastatic CRPC. To our knowledge, TLS after cabazitaxel therapy has not been reported previously.

Case presentation {#iju512070-sec-0006}
=================

A 77‐year‐old man was referred to our department for the treatment of metastatic CRPC. He was diagnosed with metastatic prostate cancer (PSA level \>1000 ng/mL, Gleason score 4 + 5, cT4N1M1) at another institution 3 years ago. He received androgen deprivation therapy involving a luteinizing hormone‐releasing agonist and nonsteroidal antiandrogen. However, he developed CRPC after 7 months. Thereafter, he received 13 cycles of 3‐weekly docetaxel (70 mg/m^2^) followed by enzalutamide for 8 months at another institution.

Laboratory test results at presentation to our hospital were as follows: PSA, 12.9 ng/mL; serum creatinine, 1.70 mg/dL; potassium, 5.1 mmol/L; corrected calcium, 9.1 mg/dL; phosphorus, 2.7 mg/dL; LDH, 622 U/L; and UA, 6.7 mg/dL.

CT showed a poorly defined prostate tumor, multiple liver metastases, and pelvic lymphadenopathy, and a bone scan showed multiple bone metastases (Fig. [1](#iju512070-fig-0001){ref-type="fig"}a--d).

![(a--c,e) CT of the abdomen. (a) Low‐defined prostate tumor (\*). (b) Multiple tumor burden in the liver (\*). (c) Pelvic lymphadenopathy (\*). (d) Bone scan. Multiple bone metastases. (e) Hemorrhage from liver metastases (\*).](IJU5-2-179-g001){#iju512070-fig-0001}

Enzalutamide was changed to cabazitaxel because of multiple liver metastases. Cabazitaxel (20 mg/m^2^) with dexamethasone (1.0 mg once daily) was initiated. He received pegfilgrastim (6 mg) subcutaneously on day 2 after treatment change as the primary prophylaxis for neutropenia. On day 3, he had fever with a temperature of 37.8°C and severe hypotension (systolic blood pressure, 75 mmHg). At this time, laboratory test results were as follows: serum creatinine, 2.85 mg/dL; potassium, 5.7 mmol/L; phosphorus, 2.8 mg/dL; UA, 11.3 mg/dL; calcium, 6.9 mg/dL; LDH, 2911 U/L; AST, 777 IU/L; ALT, 567 IU/L; and Hb, 6.1 g/dL (Table [1](#iju512070-tbl-0001){ref-type="table"}).

###### 

Patient laboratory values

                Admission   Day 3 (pre‐rasburicase)   Day 4 (post‐rasburicase)   Day 5   Day 9   Day 12 (before discharge)   Day 22 (readmission)   Normal values
  ------------- ----------- ------------------------- -------------------------- ------- ------- --------------------------- ---------------------- ---------------------
  WBC           7460        14 140                    10 100                     8990    7900    18 980                      14 360                 3900--9800/μL
  Hb            9.6         6.1                       6.6                        7.6     8.1     9.4                         9.9                    12--17.6 g/dL
  Plt           31.4        14.3                      7.3                        8.7     20.4    28.3                        32.2                   13--36.9 × 10^4^/μL
  BUN           28          52                        38                         34      36      33                          21                     8--20 mmol/L
  Creatinine    1.83        2.85                      1.92                       1.64    1.63    1.72                        1.67                   0.65--1.07
  Potassium     5.2         5.7                       4.9                        4.8     4.9     3.9                         4.4                    3.6--4.8 mmol/L
  Calcium       8.2         6.9                       6.1                        6.7     8       8.4                         7.4                    8.4--10.1 mmol/L
  Phosphorous   2.4         2.8                       2.2                        2.4     2.2     3.2                         1.7                    2.7--4.6 mmol/L
  LDH           1294        2911                      2184                       1599    1035    1502                        1935                   124--222 U/L
  AST           34          777                       200                        78      33      30                          46                     13--30 U/L
  ALT           34          567                       256                        146     62      30                          33                     10--42 U/L
  ALP           366         473                       338                        315     344     376                         773                    106--322 U/L
  UA            7.6         11.3                      0                          0.1     2.9     8.1                         8.9                    3.7--7.8 mg/dL
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Based on the laboratory and clinical findings, he was diagnosed with TLS according to the current classification system of Cairo and Bishop.[6](#iju512070-bib-0006){ref-type="ref"} His hypotension was considered to have been caused by hemorrhagic shock from intratumoral hemorrhage of the liver metastases (Fig. [1](#iju512070-fig-0001){ref-type="fig"}e).

He was admitted to the intensive care unit and received hydration therapy (3000 mL/day) and red blood cell transfusion. Correction of hyperuricemia was attempted with a recombinant uricolytic agent (rasburicase, 0.2 mg/kg). After treatment, his UA level decreased to 0 mg/dL at 16 h. Additionally, his electrolyte abnormalities almost resolved after 3 days. He was moved out of the intensive care unit on day 6 and was discharged from the hospital on day 14. However, he was readmitted to our hospital for severe pain and dyspnea 8 days after discharge. At that time, he did not want further examination, then he died of respiratory failure on the next day.

Discussion {#iju512070-sec-0007}
==========

TLS is considered a rare and potentially fatal complication of oncological treatment.

Eight cases of TLS have been reported in patients with prostate cancer, and the present case is the ninth TLS case (Table [2](#iju512070-tbl-0002){ref-type="table"}).[7](#iju512070-bib-0007){ref-type="ref"}, [8](#iju512070-bib-0008){ref-type="ref"}, [9](#iju512070-bib-0009){ref-type="ref"}, [10](#iju512070-bib-0010){ref-type="ref"}, [11](#iju512070-bib-0011){ref-type="ref"}, [12](#iju512070-bib-0012){ref-type="ref"}, [13](#iju512070-bib-0013){ref-type="ref"}, [14](#iju512070-bib-0014){ref-type="ref"} Of the nine cases, five, including our case, occurred after the administration of either chemotherapy or hormonal therapy.

###### 

Summary of existing case reports of TLS in patients with prostate cancer

  Author                      Year   Patient age   Gleason score   Disease burden                       Treatment preceding TLS                                      Treatment                                       Outcome                                               References
  --------------------------- ------ ------------- --------------- ------------------------------------ ------------------------------------------------------------ ----------------------------------------------- ----------------------------------------------------- -------------------------------------------
  Tanvetyanon and Choudhury   2004   77            Not reported    Bone, liver                          Fultamide, goserelin                                         Vigorous supportive measures                    Died 8 days following treatment                       [7](#iju512070-bib-0007){ref-type="ref"}
  Sorcher                     2004   80            3 + 3           Bone, bone marrow                    Docetaxel, daxamethasone                                     Furosemide                                      Died 40 h after treatment                             [8](#iju512070-bib-0008){ref-type="ref"}
  Wright *et al*.             2005   60            3 + 4           Bone, bone marrow                    Paclitaxel                                                   Hemodialysis                                    Died 8 days following treatment                       [9](#iju512070-bib-0009){ref-type="ref"}
  Lin *et al*.                2007   72            Not reported    Bone, liver                          Fultamide, leuprolide, dexamethasone, medroxy progesterone   Hemodialysis, furosemide, allopurinol           Died 2 weeks following treatment                      [10](#iju512070-bib-0010){ref-type="ref"}
  Kaplan *et al*.             2012   60            5 + 4           Bone, bone marrow                    Radiation therapy to shoulder                                Sodium bicarbonate                              Died 11 days following treatment                      [11](#iju512070-bib-0011){ref-type="ref"}
  Mazzoni                     2016   62            Not reported    Bone, lymph node, bladder invasion   Palliative radiation therapy, leuprolide, bicartamide        Hemodialysis, rasburicase, sodium bicarbonate   Dialysis dependent, transitioned to hospice           [12](#iju512070-bib-0012){ref-type="ref"}
  Serling‐Boyd *et al*.       2017   56            5 + 4           Bone, lymph node                     None                                                         Allopurinol, sodium bicarbonate, rasburicase    Transitioned to hospice 20 days following treatment   [13](#iju512070-bib-0013){ref-type="ref"}
  Ignaszewski and Kohlitz     2017   69            Not reported    Bone, liver                          None                                                         Sodium bicarbonate, rasburicase, hemodialysis   Died shortly thereafter                               [14](#iju512070-bib-0014){ref-type="ref"}
  Oshima                      2019   77            5 + 4           Bone, liver, lymph node              Cabazitaxel                                                  Sodium bicarbonate, rasburicase, hemodialysis   Died 23 days following treatment                      

John Wiley & Sons, Ltd

In two cases, patients developed TLS after the initiation of palliative radiation therapy for bone metastasis, whereas in two other cases, patients developed TLS spontaneously without any treatment. All patients had evidence of metastatic disease, and six of the nine cases had CRPC. TLS is defined as the presence of two or more biochemical variables within 3 days before chemotherapy or 7 days after chemotherapy in the condition of adequate hydration and the use of a UA‐lowering agent. Certain tumor and patient characteristics can be used to predict the risk of future TLS (e.g. highly proliferating and bulky malignancy, sensitivity to chemotherapy, and exposure to nephrotoxic substances, such as non‐steroidal anti‐inflammatory agents and certain antihypertensive medications).[6](#iju512070-bib-0006){ref-type="ref"}, [15](#iju512070-bib-0015){ref-type="ref"} Other potential risk factors include presence of decreased renal function and elevated LDH, phosphorus, potassium, and UA levels.[3](#iju512070-bib-0003){ref-type="ref"}

Additionally, in solid cancer, the presence of liver metastasis is a risk factor for the development of TLS, and this trend was also seen in prostate cancer (Table [2](#iju512070-tbl-0002){ref-type="table"}).[16](#iju512070-bib-0016){ref-type="ref"}

In patients having risk factors for TLS, active prevention procedures are of utmost importance to avoid fatal outcomes. Mirrakhimov *et al*. proposed a risk stratification approach for TLS prevention among patients with solid cancer (Fig. [2](#iju512070-fig-0002){ref-type="fig"}).[3](#iju512070-bib-0003){ref-type="ref"}

![Proposed evaluation for the risk of TLS and its prevention among patients with solid tumors.](IJU5-2-179-g002){#iju512070-fig-0002}

Our patient had abnormal LDH and potassium levels and renal function before cabazitaxel administration; thus, we believe that it might be better to perform TLS prevention procedures.

All patients at risk for TLS should receive hydration to improve renal perfusion and glomerular filtration and to minimize acidosis and oliguria. Hydration is the preferred method of increasing urine output, but diuretics may also be necessary.[17](#iju512070-bib-0017){ref-type="ref"} Reducing the UA level with allopurinol and, particularly, with rasburicase can preserve or improve renal function and reduce serum phosphorus levels as secondary beneficial effects.[18](#iju512070-bib-0018){ref-type="ref"} Although allopurinol prevents the formation of UA, existing UA should be excreted. The UA level may take 2 days or more to decrease, and this delay may allow the development of urate nephropathy. Moreover, despite treatment with allopurinol, xanthine may accumulate, resulting in xanthine nephropathy.[19](#iju512070-bib-0019){ref-type="ref"} Rasburicase is considered more effective than allopurinol for the prevention and treatment of TLS because it prevents xanthine accumulation and directly breaks down UA. In our case, after treatment with hydration and rasburicase, the UA level decreased to 0 mg/dL immediately and renal function improved. We believe that it is better to use rasburicase rather than allopurinol for the treatment of established TLS.

In conclusion, we experienced a rare case of TLS after a single dose of cabazitaxel for metastatic CRPC. The use of rasburicase for established TLS is beneficial to decrease the UA level, leading to renal function improvement. However, it is extremely important to assess the risk factors for TLS and to perform active prevention procedures to avoid fatal outcomes.
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